Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group.

Pharmacoepidemiology and Drug Safety
Richard AplencAlan S Gamis

Abstract

The National Cancer Institute-funded cooperative oncology group trials have improved overall survival for children with cancer from 10% to 85% and have set standards of care for adults with malignancies. Despite these successes, cooperative oncology groups currently face substantial challenges. We are working to develop methods to improve the efficiency and effectiveness of these trials. Specifically, we merged data from the Children's Oncology Group (COG) and the Pediatric Health Information Systems (PHIS) to improve toxicity monitoring, to estimate treatment-associated resource utilization and costs, and to address important clinical epidemiology questions. COG and PHIS data on patients enrolled on a phase III COG trial for de novo acute myeloid leukemia at 43 PHIS hospitals were merged using a probabilistic algorithm. Resource utilization summary statistics were then tabulated for the first chemotherapy course based on PHIS data. Of 416 patients enrolled on the phase III COG trial at PHIS centers, 392 (94%) were successfully matched. Of these, 378 (96%) had inpatient PHIS data available beginning at the date of study enrollment. For these, daily blood product usage and anti-infective exposures were tabulated and standardized...Continue Reading

References

Jun 16, 2005·Journal of Pediatric Hematology/oncology·Marc B RosenmanPhilip P Breitfeld
Jul 21, 2005·Journal of the National Cancer Institute·Elizabeth B LamontNicholas A Christakis
Dec 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michelle R MahoneyJan C Buckner
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Orit Scharf, A Dimitrios Colevas
Sep 21, 2006·Journal of the National Cancer Institute·Elizabeth B LamontUNKNOWN Cancer and Leukemia Group B
Jun 19, 2008·Pediatric Blood & Cancer·Lillian SungThomas Lehrnbecher
Oct 28, 2009·The Pediatric Infectious Disease Journal·Brian T FisherTheoklis E Zaoutis
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lee D KaiserRichard L Schilsky
Sep 13, 2011·Aesthetic Surgery Journal·Nitin ChauhanPeter A Adamson

❮ Previous
Next ❯

Citations

Dec 31, 2015·Cardiology in the Young·Kimberly E McHughMark A Scheurer
Feb 25, 2014·Seminars in Oncology Nursing·Deborah Watkins Bruner, Ann O'Mara
Feb 18, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tamara P MillerRichard Aplenc
Nov 26, 2014·Western Journal of Nursing Research·Omar M Al-RawajfahJeanne Beauchamp Hewitt
Nov 20, 2013·Pediatric Blood & Cancer·Alix E SeifRichard Aplenc
Feb 9, 2019·Leukemia & Lymphoma·Lena E WinestoneRichard Aplenc
Apr 11, 2019·Pediatric Blood & Cancer·Tamara P MillerRichard Aplenc
May 11, 2012·Pharmacoepidemiology and Drug Safety·Sebastian SchneeweissScott R Smith
Dec 25, 2013·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Shannon L MaudeRichard Aplenc
Aug 25, 2019·Prevention Science : the Official Journal of the Society for Prevention Research·Abigail A FaganDeborah Klein Walker
Mar 27, 2015·Pediatric Blood & Cancer·Henry E RiceJonathan C Routh
Nov 20, 2016·American Journal of Hematology·Lena E WinestoneRichard Aplenc
Dec 1, 2012·The Journal of Pediatrics·Lilliam V Ambroggio, Samir S Shah
Jan 29, 2019·The Journal of Pediatrics·Tellen D BennettMichael G Kahn

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.